Vantage Investment Advisors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Vantage Investment Advisors’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-86	Closed	-$5K	–	886
2017 Q4	$5K	Buy	+86	New	+$4.71K	﹤0.01%	691
2017 Q3	–	Sell	-86	Closed	-$5K	–	844
2017 Q2	$5K	Hold	86	–	–	﹤0.01%	657
2017 Q1	$5K	Buy	+86	New	+$4.24K	﹤0.01%	639

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Vantage Investment Advisors's BIVV Position: Q1 2018 in Review

Vantage Investment Advisors sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 86 shares — an estimated $5K sold.

Vantage Investment Advisors first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $5K in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Vantage Investment Advisors reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Vantage Investment Advisors sold 86 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $5K.
Vantage Investment Advisors first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
Vantage Investment Advisors's Bioverativ Inc. Common Stock position peaked at $5K in Q4 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Vantage Investment Advisors's 13F filing for Q1 2018, filed 10 May 2018.